Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Abdominal Radiology
Erschienen in: Abdominal Radiology 2/2018

14.12.2017

Response assessment in pancreatic ductal adenocarcinoma: role of imaging

verfasst von: Vinit Baliyan, Hamed Kordbacheh, Anushri Parakh, Avinash Kambadakone

Erschienen in: Abdominal Radiology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive gastrointestinal (GI) malignancy with poor 5-year survival rate. Advances in surgical techniques and introduction of novel combination chemotherapy and radiation therapy regimens have necessitated the need for biomarkers for assessment of treatment response. Conventional imaging methods such as RECIST have been used for response evaluation in clinical trials particularly in patients with metastatic PDAC. However, the role of these approaches for assessing response to loco-regional and systemic therapies is limited due to complex morphological and histological nature of PDAC. Determination of tumor resectability after neoadjuvant therapy remains a challenge. This review article provides an overview of the challenges and limitations of response assessment in PDAC and reviews the current evidence for the utility of novel morphological and functional imaging tools in this disease.
Literatur
1.
2.
Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA 60(5):277–300PubMed
3.
Ferrone CR, Brennan MF, Gonen M, et al. (2008) Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg 12(4):701–706CrossRefPubMed
4.
Winter JM, Cameron JL, Campbell KA, et al. (2006) 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg. 10(9):1199–1210 ((discussion 1210–1211))CrossRefPubMed
5.
Ferrone CR, Pieretti-Vanmarcke R, Bloom JP, et al. (2012) Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery 152(3 Suppl 1):S43–S49CrossRefPubMedPubMedCentral
6.
7.
Ko AH, Quivey JM, Venook AP, et al. (2007) A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 68(3):809–816CrossRefPubMed
8.
Ben-Josef E, Shields AF, Vaishampayan U, et al. (2004) Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer. Int J Radiat Oncol Biol Phys 59(2):454–459CrossRefPubMed
9.
Bittoni A, Santoni M, Lanese A, et al. (2014) Neoadjuvant therapy in pancreatic cancer: an emerging strategy. Gastroenterol Res Pract 2014:183852CrossRefPubMedPubMedCentral
10.
11.
12.
Katz MHG, Fleming JB, Bhosale P, et al. (2012) Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer 118(23):5749–5756CrossRefPubMed
13.
Ferrone CR, Marchegiani G, Hong TS, et al. (2015) Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg 261(1):12–17CrossRefPubMedPubMedCentral
14.
Valls C, Andía E, Sanchez A, et al. (2002) Dual-phase helical CT of pancreatic adenocarcinoma: assessment of resectability before surgery. Am J Roentgenol 178(4):821–826CrossRef
15.
Wong JC, Raman S (2010) Surgical resectability of pancreatic adenocarcinoma: CTA. Abdom Imaging 35(4):471–480CrossRefPubMed
16.
Brennan DDD, Zamboni GA, Raptopoulos VD, Kruskal JB (2007) Comprehensive preoperative assessment of pancreatic adenocarcinoma with 64-section volumetric CT. Radiogr Rev Publ Radiol Soc N Am Inc 27(6):1653–1666
17.
Evans DB, Varadhachary GR, Crane CH, et al. (2008) Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol Off J Am Soc Clin Oncol 26(21):3496–3502CrossRef
18.
Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 7(4):e1000267CrossRefPubMedPubMedCentral
19.
Varadhachary GR, Wolff RA, Crane CH, et al. (2008) Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol Off J Am Soc Clin Oncol 26(21):3487–3495CrossRef
20.
Heinrich S, Pestalozzi BC, Schäfer M, et al. (2008) Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. J Clin Oncol Off J Am Soc Clin Oncol 26(15):2526–2531CrossRef
21.
Palmer DH, Stocken DD, Hewitt H, et al. (2007) A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol 14(7):2088–2096CrossRefPubMed
22.
Le Scodan R, Mornex F, Girard N, et al. (2009) Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review. Ann Oncol Off J Eur Soc Med Oncol 20(8):1387–1396CrossRef
23.
Chatterjee D, Katz MH, Rashid A, et al. (2012) Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma. Am J Surg Pathol 36(3):409–417CrossRefPubMedPubMedCentral
24.
Chatterjee D, Rashid A, Wang H, et al. (2012) Tumor invasion of muscular vessels predicts poor prognosis in patients with pancreatic ductal adenocarcinoma who have received neoadjuvant therapy and pancreaticoduodenectomy. Am J Surg Pathol 36(4):552–559CrossRefPubMedPubMedCentral
25.
26.
Tempero MA, Arnoletti JP, Behrman SW, et al. (2012) Pancreatic adenocarcinoma, version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Cancer Netw 10(6):703–713CrossRef
27.
Laurence JM, Tran PD, Morarji K, et al. (2011) A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer. J Gastrointest Surg Off J Soc Surg Aliment Tract. 15(11):2059–2069CrossRef
28.
Crane CH, Varadhachary GR, Yordy JS, et al. (2011) Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol Off J Am Soc Clin Oncol. 29(22):3037–3043CrossRef
29.
De Jesus-Acosta A, Oliver GR, Blackford A, et al. (2012) A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma. Cancer Chemother Pharmacol. 69(2):415–424CrossRefPubMed
30.
Herman JM, Swartz MJ, Hsu CC, et al. (2008) Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol Off J Am Soc Clin Oncol. 26(21):3503–3510CrossRef
31.
Von Hoff DD, Ramanathan RK, Borad MJ, et al. (2011) Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol Off J Am Soc Clin Oncol. 29(34):4548–4554CrossRef
32.
Conroy T, Desseigne F, Ychou M, et al. (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 364(19):1817–1825CrossRefPubMed
33.
Kunzmann V, Ramanathan RK, Goldstein D, et al. (2017) Tumor reduction in primary and metastatic pancreatic cancer lesions with nab-paclitaxel and gemcitabine. Pancreas. 46(2):203–208CrossRefPubMed
34.
Galizia MS, Töre HG, Chalian H, Yaghmai V (2011) Evaluation of hepatocellular carcinoma size using two-dimensional and volumetric analysis: effect on liver transplantation eligibility. Acad Radiol. 18(12):1555–1560CrossRefPubMed
35.
Hartman DJ, Krasinskas AM (2012) Assessing treatment effect in pancreatic cancer. Arch Pathol Lab Med. 136(1):100–109CrossRefPubMed
36.
Xia BT, Fu B, Wang J, et al. (2017) Does radiologic response correlate to pathologic response in patients undergoing neoadjuvant therapy for borderline resectable pancreatic malignancy? J Surg Oncol. 115(4):376–383CrossRefPubMed
37.
He J, Page AJ, Weiss M, et al. (2014) Management of borderline and locally advanced pancreatic cancer: where do we stand? World J Gastroenterol. 20(9):2255–2266CrossRefPubMedPubMedCentral
38.
Cassinotto C, Mouries A, Lafourcade J-P, et al. (2014) Locally advanced pancreatic adenocarcinoma: reassessment of response with CT after neoadjuvant chemotherapy and radiation therapy. Radiology. 273(1):108–116CrossRefPubMed
39.
Dudeja V, Greeno EW, Walker SP, Jensen EH (2013) Neoadjuvant chemoradiotherapy for locally advanced pancreas cancer rarely leads to radiological evidence of tumour regression. HPB. 15(9):661–667CrossRefPubMed
40.
41.
Yu L, Leng S, McCollough CH (2012) Dual-energy CT-based monochromatic imaging. Am J Roentgenol. 199(5 Suppl):S9–S15CrossRef
42.
Choi H (2008) Response evaluation of gastrointestinal stromal tumors. Oncologist 13(Suppl 2):4–7CrossRefPubMed
43.
Tian F, Hayano K, Kambadakone AR, Sahani DV (2015) Response assessment to neoadjuvant therapy in soft tissue sarcomas: using CT texture analysis in comparison to tumor size, density, and perfusion. Abdom Imaging 40(6):1705–1712CrossRefPubMed
44.
Kambadakone A, Yoon SS, Kim T-M, et al. (2015) CT perfusion as an imaging biomarker in monitoring response to neoadjuvant bevacizumab and radiation in soft-tissue sarcomas: comparison with tumor morphology, circulating and tumor biomarkers, and gene expression. Am J Roentgenol. 204(1):W11–W18CrossRef
45.
46.
De Cecco CN, Darnell A, Rengo M, et al. (2012) Dual-energy CT: oncologic applications. Am J Roentgenol. 199(5 Suppl):S98–S105CrossRef
47.
Chu AJ, Lee JM, Lee YJ, et al. (2012) Dual-source, dual-energy multidetector CT for the evaluation of pancreatic tumours. Br J Radiol. 85(1018):e891–e898CrossRefPubMedPubMedCentral
48.
Patel BN, Thomas JV, Lockhart ME, Berland LL, Morgan DE (2013) Single-source dual-energy spectral multidetector CT of pancreatic adenocarcinoma: optimization of energy level viewing significantly increases lesion contrast. Clin Radiol. 68(2):148–154CrossRefPubMed
49.
Macari M, Spieler B, Kim D, et al. (2010) Dual-source dual-energy MDCT of pancreatic adenocarcinoma: initial observations with data generated at 80 kVp and at simulated weighted-average 120 kVp. Am J Roentgenol. 194(1):W27–W32CrossRef
50.
Stiller W, Skornitzke S, Fritz F, et al. (2015) Correlation of quantitative dual-energy computed tomography iodine maps and abdominal computed tomography perfusion measurements: are single-acquisition dual-energy computed tomography iodine maps more than a reduced-dose surrogate of conventional computed tomography perfusion? Invest Radiol. 50(10):703–708CrossRefPubMed
51.
Baxa J, Matouskova T, Krakorova G, et al. (2015) Dual-phase dual-energy CT in patients treated with Erlotinib for advanced non-small cell lung cancer: possible benefits of iodine quantification in response assessment. Eur Radiol.
52.
Baxa J, Vondráková A, Matoušková T, et al. (2014) Dual-phase dual-energy CT in patients with lung cancer: assessment of the additional value of iodine quantification in lymph node therapy response. Eur Radiol. 24(8):1981–1988CrossRefPubMed
53.
Li Y, Shi G, Wang S, Wang S, Wu R (2013) Iodine quantification with dual-energy CT: phantom study and preliminary experience with VX2 residual tumour in rabbits after radiofrequency ablation. Br J Radiol. 86(1029):20130143CrossRefPubMedPubMedCentral
54.
55.
Ganeshan B, Goh V, Mandeville HC, et al. (2013) Non-small cell lung cancer: histopathologic correlates for texture parameters at CT. Radiology. 266(1):326–336CrossRefPubMed
56.
Ganeshan B, Skogen K, Pressney I, Coutroubis D, Miles K (2012) Tumour heterogeneity in oesophageal cancer assessed by CT texture analysis: preliminary evidence of an association with tumour metabolism, stage, and survival. Clin Radiol. 67(2):157–164CrossRefPubMed
57.
Goh V, Ganeshan B, Nathan P, et al. (2011) Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker. Radiology. 261(1):165–171CrossRefPubMed
58.
Chen X, Oshima K, Schott D, et al. (2017) Assessment of treatment response during chemoradiation therapy for pancreatic cancer based on quantitative radiomic analysis of daily CTs: an exploratory study. PloS One. 12(6):e0178961CrossRefPubMedPubMedCentral
59.
Niwa T, Ueno M, Ohkawa S, et al. (2009) Advanced pancreatic cancer: the use of the apparent diffusion coefficient to predict response to chemotherapy. Br J Radiol. 82(973):28–34CrossRefPubMed
60.
Cuneo KC, Chenevert TL, Ben-Josef E, et al. (2014) A pilot study of diffusion-weighted MRI in patients undergoing neoadjuvant chemoradiation for pancreatic cancer. Transl Oncol. 7(5):644–649CrossRefPubMedPubMedCentral
61.
Granata V, Fusco R, Setola SV, et al. (2017) Early radiological assessment of locally advanced pancreatic cancer treated with electrochemotherapy. World J Gastroenterol. 23(26):4767–4778CrossRefPubMedPubMedCentral
62.
Shenoy-Bhangle A, Baliyan V, Kordbacheh H, Guimaraes AR, Kambadakone A (2017) Diffusion weighted magnetic resonance imaging of liver: principles, clinical applications and recent updates. World J Hepatol. 9(26):1081–1091CrossRefPubMedPubMedCentral
63.
Bang S, Chung HW, Park SW, et al. (2006) The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. J Clin Gastroenterol. 40(10):923–929CrossRefPubMed
64.
Kittaka H, Takahashi H, Ohigashi H, et al. (2013) Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in predicting the pathologic response to preoperative chemoradiation therapy in patients with resectable T3 pancreatic cancer. World J Surg. 37(1):169–178CrossRefPubMed
65.
Bjerregaard JK, Fischer BM, Vilstrup MH, et al. (2011) Feasibility of FDG-PET/CT imaging during concurrent chemo-radiotherapy in patients with locally advanced pancreatic cancer. Acta Oncol Stockh Swed. 50(8):1250–1252CrossRef
66.
Patel M, Hoffe S, Malafa M, et al. (2011) Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer. J Surg Oncol. 104(2):155–161CrossRefPubMedPubMedCentral
67.
Choi M, Heilbrun LK, Venkatramanamoorthy R, et al. (2010) Using 18F-fluorodeoxyglucose positron emission tomography to monitor clinical outcomes in patients treated with neoadjuvant chemo-radiotherapy for locally advanced pancreatic cancer. Am J Clin Oncol. 33(3):257–261PubMed
68.
van Kouwen MCA, Laverman P, van Krieken JH, et al. (2005) FDG-PET in the detection of early pancreatic cancer in a BOP hamster model. Nucl Med Biol. 32(5):445–450CrossRefPubMed
69.
Fendrich V, Schneider R, Maitra A, et al. (2011) Detection of precursor lesions of pancreatic adenocarcinoma in PET-CT in a genetically engineered mouse model of pancreatic cancer. Neoplasia 13(2):180–186CrossRefPubMedPubMedCentral
70.
Ramanathan RK, Goldstein D, Korn RL, et al. (2016) Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas. Ann Oncol Off J Eur Soc Med Oncol. 27(4):648–653CrossRef
71.
Toesca DAS, Pollom EL, Poullos PD, et al. (2017) Assessing local progression after stereotactic body radiation therapy for unresectable pancreatic adenocarcinoma: CT versus PET. Pract Radiat Oncol. 7(2):120–125CrossRefPubMed
72.
Heinrich S, Schäfer M, Weber A, et al. (2008) Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial. Ann Surg. 248(6):1014–1022CrossRefPubMed
73.
Chang BK, Timmerman RD (2007) Stereotactic body radiation therapy: a comprehensive review. Am J Clin Oncol. 30(6):637–644CrossRefPubMed
74.
Choi HJ, Lee JW, Kang B, et al. (2014) Prognostic significance of volume-based FDG PET/CT parameters in patients with locally advanced pancreatic cancer treated with chemoradiation therapy. Yonsei Med J. 55(6):1498–1506CrossRefPubMedPubMedCentral
75.
Davalos RV, Mir LM, Rubinsky B (2005) Tissue ablation with irreversible electroporation. Ann Biomed Eng. 33(2):223–231CrossRefPubMed
76.
Martin RCG (2015) Use of irreversible electroporation in unresectable pancreatic cancer. Hepatobiliary Surg Nutr. 4(3):211–215PubMedPubMedCentral
77.
Martin RCG (2015) Irreversible electroporation of locally advanced pancreatic neck/body adenocarcinoma. J Gastrointest Oncol. 6(3):329–335PubMedPubMedCentral
78.
Martin RCG, Kwon D, Chalikonda S, et al. (2015) Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy. Ann Surg. 262(3):486–494 ((discussion 492–494))CrossRefPubMed
79.
Martin RCG, McFarland K, Ellis S, Velanovich V (2012) Irreversible electroporation therapy in the management of locally advanced pancreatic adenocarcinoma. J Am Coll Surg. 215(3):361–369CrossRefPubMed
80.
Martin RCG, McFarland K, Ellis S, Velanovich V (2013) Irreversible electroporation in locally advanced pancreatic cancer: potential improved overall survival. Ann Surg Oncol. 20(S3):443–449CrossRef
81.
Scheffer HJ, Nielsen K, de Jong MC, et al. (2014) Irreversible electroporation for nonthermal tumor ablation in the clinical setting: a systematic review of safety and efficacy. J Vasc Interv Radiol. 25(7):997–1011 ((quiz 1011))CrossRefPubMed
82.
Ansari D, Kristoffersson S, Andersson R, Bergenfeldt M (2017) The role of irreversible electroporation (IRE) for locally advanced pancreatic cancer: a systematic review of safety and efficacy. Scand J Gastroenterol. 52(11):1165–1171CrossRefPubMed
83.
Jaroszeski MJ, Dang V, Pottinger C, et al. (2000) Toxicity of anticancer agents mediated by electroporation in vitro. Anticancer Drugs. 11(3):201–208CrossRefPubMed
84.
Akinwande O, Ahmad SS, Van Meter T, Schulz B, Martin RCG (2015) CT findings of patients treated with irreversible electroporation for locally advanced pancreatic cancer. J Oncol. 2015:680319CrossRefPubMedPubMedCentral
85.
Vroomen LGPH, Scheffer HJ, Melenhorst MCAM, et al. (2017) MR and CT imaging characteristics and ablation zone volumetry of locally advanced pancreatic cancer treated with irreversible electroporation. Eur Radiol. 27(6):2521–2531CrossRefPubMed
Metadaten
Titel
Response assessment in pancreatic ductal adenocarcinoma: role of imaging
verfasst von
Vinit Baliyan
Hamed Kordbacheh
Anushri Parakh
Avinash Kambadakone
Publikationsdatum
14.12.2017
Verlag
Springer US
Erschienen in
Abdominal Radiology / Ausgabe 2/2018
Print ISSN: 2366-004X
Elektronische ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-017-1434-7

Weitere Artikel der Ausgabe 2/2018

Abdominal Radiology 2/2018 Zur Ausgabe

OriginalPaper

Applicability of current NCCN Guidelines for pancreatic adenocarcinoma resectability: analysis and pitfalls

OriginalPaper

Characterizing indeterminate liver lesions in patients with localized pancreatic cancer at the time of diagnosis

OriginalPaper

Utility of (18) F-FDG PET/CT and CECT in conjunction with serum CA 19-9 for detecting recurrent pancreatic adenocarcinoma

OriginalPaper

Imaging of post-operative pancreas and complications after pancreatic adenocarcinoma resection

OriginalPaper

Extrapancreatic perineural invasion in pancreatic adenocarcinoma

OriginalPaper

Multi-institutional survey on imaging practice patterns in pancreatic ductal adenocarcinoma

Neu im Fachgebiet Radiologie

18.04.2024 | Pädiatrische Notfallmedizin | Nachrichten

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

08.04.2024 | Andrologie | Nachrichten

Wie toxische Männlichkeit der Gesundheit von Männern schadet

29.03.2024 | Diagnostische Radiologie | Nachrichten

Studie bestätigt Potenzial von KI in der Radiologie

26.03.2024 | Koronare Herzerkrankung | Nachrichten

Quantitative Angiografie könnte IVUS-Alternative darstellen
weitere anzeigen

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen